Shiba Inu (SHIB) Explodes 15% Daily, Bitcoin (BTC) Maintains $68K (Market Watch)
SHIB and WIF are the top gainers from the larger-cap alts.
Bitcoin’s price has been on a wild ride in the past few days, first heading north to over $70,00 before it dumped to $67,000 a day later.
The altcoins have recovered some of yesterday’s losses, and most have turned green. SHIB and WIF lead the pack from the meme coin realm with massive double-digit surges.
BTC Reclaims and Calms at $68K
The largest cryptocurrency by market cap experienced a volatile five-day trading period last week after the news surrounding the eventual approval of spot Ethereum ETFs by the US SEC. The asset skyrocketed to a multi-week peak at the start of it of nearly $72,000, but it dumped to under $66,500 on Thursday – just hours before the SEC’s actual approval.
It regained some traction on Friday and during the weekend as its price went to $69,000. It retraced slightly on Monday before another leg up resulted in breaking above $70,000 for the first time in about a week.
Yet, the bulls failed to maintain this run and BTC dumped hard yesterday to just over $67,000. Still, bitcoin bounced off and neared $69,000 once more hours ago but was stopped there and now sits inches above $68,000.
Its market cap remains below $1.350 trillion, but its dominance over the alts has taken another minor hit and is down to 49.6%.
SHIB, WIF on a Roll
The meme coins have been among the top performers in the past 24 hours. SHIB is at the forefront of the massive surge, gaining 15% overnight. Moreover, SHIB surpassed Cardano to become the 11th largest cryptocurrency by market cap, as reported earlier.
WIF is the other massive gainer from the larger-cap alts. The asset has soared by 20% in a day and now trades close to $4.
SOL, TON, RNDR, and ATOM are with minor gains from the larger-cap alts, while ETH is down by 0.4% but still trades above $3,800.
The total crypto market cap has recovered $35 billion overnight and sits above $2.7 trillion on CG.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
